In concordance to this, we have previously shown IL6 can drive destabilized vasculature with loss of pericytes via activation of the ANG2 signaling and that anti-IL6 therapy can normalize this effect in xenograft models of ovarian cancer (8). This evidence concerns the gene IL6 and ovarian carcinoma.